Due to the otherwise dismal course of DLBCL, staging should be completed within a few weeks to initiate timely therapy thereafter. The current annual incidences are 29,100 cases in the United States and 26,000 in Western Europe, with a predicted increase in the next years. In the context of the ongoing development of targeted therapies, new RT indications may evolve.ĭiffuse large B‑cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL), constituting 31% of all NHL. With the use of PET-guided treatment, RT is indicated for patients with metabolically active tumors. ![]() RT remains an integral part of the treatment repertoire of DLBCL. Additionally, RT may be used in the treatment context of various subtypes of DLBCL as well as in the recurrent or refractory treatment situation. Conformal techniques shall be used for target volume coverage, with a risk–benefit evaluation for the individual patient. For RT planning, PET information before and after immunochemotherapy shall be used, with either a PET-CT in the RT treatment position or an image fusion to the planning CT. ![]() RT shall be administered to all patients with localized positron emission tomography(PET)-positive residues after completion of immunochemotherapy and should use a dose of 30–40 Gray in normofractionation. Additional literature is presented to provide a comprehensive background for the published recommendations. The following article reviews the evidence and recommendations given in the current German evidence-based guideline on DLBCL regarding RT and summarizes pivotal aspects. The publication of the national evidence-based guideline on DLBCL prompted us to review relevant passages on radiation oncology. However, there are conflicting data on the role and impact of consolidative radiation therapy (RT). Delinasios), All rights reserved.Diffuse large B‑cell lymphoma (DLBCL) is an aggressive lymphoma subtype treated successfully with immunochemotherapy. Copyright © 2021 International Institute of Anticancer Research (Dr.Conclusion: IG-IMRT following systemic therapy seems to be associated with a favorable survival and toxicity profile in patients with EN-NHL. Regarding toxicities, IMRT was associated with less acute and chronic adverse events. Complete responders after primary treatments had a significantly higher 5-year progression-free (p<0.001) and overall survival (p=0.003) in comparison with those without a complete response. There was non-significant longer survival following IMRT compared with 3DCRT in terms of 5-year OS (p=0.16). Patients treated with IMRT experienced higher overall responde rate than patients who received 3DCRT (85% vs. ![]() Results: The median follow-up was 42 months. Patients and Methods: Forty-eight patients who underwent irradiation between 20 were identified. This analysis compared conventional radiotherapy (CRT) and IMRT outcomes for head and neck aggressive extranodal non-Hodgkin lymphomas (EN-NHL). Background/Aim: Image-guided intensity-modulated radiotherapy (IG-IMRT) is increasingly being used to treat patients with head and neck malignancies.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |